Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Labcorp HoldingsFRA:N6B +6.84%82 EV-to-FCF is 21.79 as of Jul. 18, 2026, which is 10% above its 10-year median of 19.80. GuruFocus rates FRA:N6B with a GF Score™ of 82/100 and a GF Value™ of €233.75 (Fairly Valued). The stock has 6 warning signs investors should review. Among 99 Medical Diagnostics & Research companies, Labcorp Holdings ranks better than 55.56% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Labcorp Holdings's Enterprise Value is €25,915 Mil.
Labcorp Holdings's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was €1,189 Mil. Therefore, Labcorp Holdings's EV-to-FCF for today is 21.79.
The historical rank and industry rank for Labcorp Holdings's EV-to-FCF or its related term are showing as below:
FRA:N6B'
s EV-to-FCF Range Over the Past 10 Years
Min: 9.51 Med: 19.8 Max: 35.62
Current: 21.32
During the past 13 years, the highest EV-to-FCF of Labcorp Holdings was 35.62. The lowest was 9.51. And the median was 19.80.
FRA:N6B's EV-to-FCF is ranked better than 55.56% of 99
companies
in the Medical Diagnostics & Research industry
Industry Median: 27.75
vs FRA:N6B: 21.32
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Labcorp Holdings's PE Ratio (TTM) for today is calculated as:
Labcorp Holdings's share price for today is €250.00.
Labcorp Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €9.709.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Labcorp Holdings EV-to-FCF Related Terms
Labcorp Holdings EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Labcorp Holdings's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Labcorp Holdings's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Labcorp Holdings EV-to-FCF vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Labcorp Holdings's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Labcorp Holdings's EV-to-FCF falls into.
Labcorp Holdings's current Enterprise Value is €25,915 Mil.
Labcorp Holdings's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €1,189 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Labcorp Holdings (FRA:N6B) has a EV-to-FCF of 21.79 as of Jul. 18, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Labcorp Holdings and its competitors. This is 10% above median its historical median of 19.80. Over the past decade, Labcorp Holdings' EV-to-FCF has ranged from 9.51 to 35.62. According to the industry distribution chart, Labcorp Holdings ranks #44 out of 99 companies in the Medical Diagnostics & Research industry, placing it in the top 44.4%.
Is Labcorp Holdings' EV-to-FCF too high?
Labcorp Holdings' current EV-to-FCF of 21.79 is 10% above median its 10-year median of 19.80. Over the past 10 years, this metric has ranged from a low of 9.51 to a high of 35.62. The Medical Diagnostics & Research industry median EV-to-FCF is 27.75. Labcorp Holdings' value of 21.79 is 21.5% below this industry median. Based on the distribution chart, Labcorp Holdings ranks #44 out of 99 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Labcorp Holdings has a GF Score™ of 82/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Labcorp Holdings' EV-to-FCF compare to DGX and GH?
According to the Medical Diagnostics & Research industry distribution chart, Labcorp Holdings ranks #44 out of 99 companies for EV-to-FCF. This puts Labcorp Holdings in the upper half of its industry. The industry median EV-to-FCF is 27.75. Labcorp Holdings' value of 21.79 is 21.5% below this benchmark. Historically, Labcorp Holdings' own EV-to-FCF has ranged from 9.51 to 35.62 over the past decade. While the company's 10-year median is 19.80 vs. the industry median of 27.75, Labcorp Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Diagnostics & Research company?
The median EV-to-FCF among Medical Diagnostics & Research companies is 27.75, based on 99 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Labcorp Holdings's current EV-to-FCF of 21.79 is 21.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Labcorp Holdings and its competitors. For the Medical Diagnostics & Research industry, the median EV-to-FCF is 27.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Labcorp Holdings's current EV-to-FCF is 21.79, which is 10% above median its own 10-year median of 19.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Labcorp Holdings stock overvalued right now?
Based on GuruFocus' analysis, Labcorp Holdings (FRA:N6B) is currently considered Fairly Valued. The stock's GF Value™ is €233.75, compared to a current price of €250.00 — trading 7% above its estimated fair value. The current EV-to-FCF is 21.79, which is 10% above median its 10-year median of 19.80 and 21.5% below the Medical Diagnostics & Research industry median of 27.75. Labcorp Holdings' overall GF Score™ is 82/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Labcorp Holdings (FRA:N6B), the current EV-to-FCF is 21.79 as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Labcorp Holdings (FRA:N6B) Overvalued in 2026?
Based on GuruFocus' analysis, Labcorp Holdings stock appears to be overvalued.
The current stock price of €250.00 is trading 7% above its estimated GF Value™ of €233.75.
GuruFocus considers Labcorp Holdings to be Fairly Valued.
Key valuation signals for FRA:N6B:
EV-to-FCF: 21.79 (10% above median its 10-year median of 19.80)
GF Value™: €233.75 vs. price of €250.00 (7% above fair value)
Industry Position: 21.5% below the Medical Diagnostics & Research median (#44 of 99)
No single metric tells the full story. See the FRA:N6B stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Labcorp is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from uncomplicated routine blood and urine screens to complex oncology and genomic testing.
82GF Score
Get the complete analysis for FRA:N6B
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:N6B has been successfully added to your 
